Revenue: As of FY2026 Q2, the actual value is USD 44.69 M, beating the estimate of USD 42.4 M.

EPS: As of FY2026 Q2, the actual value is USD -2.56, beating the estimate of USD -2.6556.

EBIT: As of FY2026 Q2, the actual value is USD -166.71 M.

GRAIL, Inc. reported its financial results for the second quarter and first half of 2026.

Segment Revenue

• Total Revenue (Q2 2026): $44.7 million, an increase of $9.1 million or 26% year-over-year.
  • Screening Revenue (Q2 2026): $42,642 thousand, compared to $34,379 thousand in Q2 2025.
  • Development Services Revenue (Q2 2026): $2,045 thousand, compared to $1,165 thousand in Q2 2025.
• Galleri Test Revenue (Q2 2026): $42.6 million, grew 24% year-over-year.
• Galleri Test Revenue (H1 2026): $82.5 million, grew 30% year-over-year.

Operational Metrics

• Net Loss (Q2 2026): - $110.2 million, an improvement of $3.7 million or 3% compared to - $113.985 million in Q2 2025.
• Net Loss (H1 2026): - $203,434 thousand, compared to - $220,198 thousand in H1 2025.
• Gross Loss (Q2 2026): - $12.6 million, an improvement of $5.2 million or 29% compared to - $17,775 thousand in Q2 2025.
• Gross Loss (H1 2026): - $26,873 thousand, compared to - $37,704 thousand in H1 2025.
• Adjusted Gross Profit (Q2 2026): $21.6 million, an increase of $5.4 million or 34% compared to $16,114 thousand in Q2 2025.
• Adjusted Gross Profit (H1 2026): $41,253 thousand, compared to $30,419 thousand in H1 2025.
• Adjusted EBITDA (Q2 2026): - $90.3 million, an increase in adjusted EBITDA loss of $11.9 million or 15% compared to - $78,322 thousand in Q2 2025.
• Adjusted EBITDA (H1 2026): - $170,192 thousand, compared to - $177,057 thousand in H1 2025.
• Loss from Operations (Q2 2026): - $173,783 thousand, compared to - $158,854 thousand in Q2 2025.
• Interest Income (Q2 2026): $7,230 thousand, compared to $6,809 thousand in Q2 2025.
• Benefit from Income Taxes (Q2 2026): $56,461 thousand, compared to $38,871 thousand in Q2 2025.

Operating Costs (Q2 2026)

• Cost of Screening Revenue: $23,347 thousand, compared to $19,346 thousand in Q2 2025.
• Cost of Development Services Revenue: $434 thousand, compared to $501 thousand in Q2 2025.
• Cost of Revenue — Amortization of Intangible Assets: $33,472 thousand, consistent with Q2 2025.
• Research and Development: $47,429 thousand, compared to $46,626 thousand in Q2 2025.
• Sales and Marketing: $37,657 thousand, compared to $28,539 thousand in Q2 2025.
• General and Administrative: $50,708 thousand, compared to $37,914 thousand in Q2 2025.
• Intangible and Other Assets Impairment: $25,423 thousand, compared to $28,000 thousand in Q2 2025.

Cash Position

• Cash, cash equivalents, and short-term marketable securities: $861.6 million as of June 30, 2026.

Unique Metrics

• Galleri Test Volume (Q2 2026): More than 61,000, increased 35% year-over-year.
• Galleri Test Volume (H1 2026): More than 117,000, increased 42% year-over-year.

Outlook / Guidance

GRAIL, Inc. anticipates an FDA advisory committee in the fall to review the Premarket Approval (PMA) application for the Galleri multi-cancer early detection blood test. The company completed a $110 million equity financing with Samsung C&T Corporation and Samsung Electronics Co., Ltd. GRAIL, Inc. intends to collaborate with Samsung C&T to commercialize the Galleri test in South Korea, with potential expansion into other Asian markets subject to regulatory approvals.